<DOC>
	<DOC>NCT00361322</DOC>
	<brief_summary>The concept behind our study was to combine an effect of antibiotic and anti-inflammatory agents for a more efficient acne therapy directed at the factors involved in the pathophysiology of the disease. For this purpose we evaluated a combination of clindamycin phosphate and salicylic acid in a non-irritating carrier.</brief_summary>
	<brief_title>Efficacy and Safety of a Preparation Containing an Antibiotic and Anti-Inflammatory Agent in Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Salicylic Acid</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>mild to moderate acne vulgaris; at least 5 lesions on the face; a onemonth washout period was established for any topical or systemic drug use for treatment of acne vulgaris. acne that was primarily truncal, nodular, or due to secondary causes/internal disease; pregnancy, breastfeeding, or intention to become pregnant; another dermatological disease of the face; significant systemic disease; any drug/alcohol addiction; interacting medication; known hypersensitivity to study medications; history of chronic disease treated with medications which might affect acne condition and treatment outcome (e.g. corticosteroids, lithium, isoniazid, antiandrogens, phenytoin, phenobarbital) in the preceding month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>